Publication Spotlight — September 2026 Posted: 2026-09-06 Source: The Lancet News Type: Features & Briefs share Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial Phase 3 SWOG/NRG S1914 trial findings in The Lancet, led by Radiation Oncology Chair Megan Daly, MD, show adding atezolizumab to SBRT did not improve survival in high-risk early-stage NSCLC. View more on The Lancet Media Contacts Matt Miller Director mrmille2@uci.edu Communications & PR Office Associated Links PubMed Related Faculty/Staff Megan Daly, MD Professor and Chair — Radiation Oncology